What is tafasitamab made from?

Tafasitamab is a humanized, Fcâengineered monoclonal antibody designed to bind to the CD19 protein on Bâcells, enhancing immuneâmediated killing of malignant cells.

What company makes tafasitamab (Monjuvi/Minjuvi)?

Tafasitamab is manufactured and marketed by Incyte Corporation, coâdeveloped with or licensed from MorphoSys, under the brand names Monjuvi and Minjuvi.

Tafasitamab‑cxix bulk supplier for pharma manufacturers

Tafasitamab‑Cxix 200 mg Suppliers & Bulk Manufacturers

Q: What is tafasitamab used for?

Tafasitamabâcxix is used as part of a combination immunotherapy regimen for adult patients with relapsed or refractory diffuse large Bâcell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.

Available Forms: Injection

Available Strengths: 200 mg

Reference Brands: Monjuvi (USA), Minjuvi (EU)

Category: Oncology Cancer Care

Tafasitamab‑cxix is a humanized, Fc‑engineered monoclonal antibody targeting the CD19 protein on B‑cell surfaces. It is used intravenously in combination with other therapies (e.g., lenalidomide) to treat relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) in adults not eligible for stem cell transplant. The antibody recruits immune effector cells to kill malignant B cells. It is supplied as a 200 mg powder for infusion. Tafasitamab represents a modern immunotherapy option in aggressive B‑cell lymphomas.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Tafasitamab‑cxix is a targeted cancer immunotherapy in the form of a humanized, Fc‑modified monoclonal antibody directed against the CD19 antigen, a protein expressed on the surface of B‑cells, including malignant cells in B‑cell non‑Hodgkin lymphomas. By binding to CD19, tafasitamab flags cancerous B‑cells for destruction by the immune system, enhancing immune‑mediated cytotoxic mechanisms like antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cellular phagocytosis (ADCP). It is primarily indicated for treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant, typically administered in combination with lenalidomide during early cycles and followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. The drug is supplied as a lyophilized 200 mg vial for intravenous infusion by healthcare professionals. Tafasitamab has been approved in the United States as Monjuvi and in the European Union and United Kingdom as Minjuvi (tafasitamab) with conditional authorizations. Its development represents an important step in expanding therapeutic options for patients with aggressive B‑cell lymphomas refractory to standard treatments, offering a biologic approach that leverages immune engagement against tumor cells.

Tafasitamab‑Cxix — third party manufacturing & bulk supply

Tafasitamab‑Cxix 200 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tafasitamab‑Cxix is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tafasitamab‑Cxix listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tafasitamab‑Cxix →

Back to Listing

Frequently Asked Questions

Tafasitamab‑cxix is used as part of a combination immunotherapy regimen for adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.

Tafasitamab is a humanized, Fc‑engineered monoclonal antibody designed to bind to the CD19 protein on B‑cells, enhancing immune‑mediated killing of malignant cells.

The primary trade names for tafasitamab are

Tafasitamab is manufactured and marketed by Incyte Corporation, co‑developed with or licensed from MorphoSys, under the brand names Monjuvi and Minjuvi.

The generic name of Monjuvi is

The brand names for tafasitamab include

Tafasitamab is produced in regulated biopharmaceutical manufacturing facilities designated by its manufacturers, ensuring quality for oncology use globally.